Yin H, Okada N, Takagi M
Molecular Pathology, Department of Oral Restitution, Graduate School, Tokyo Medical and Dental University, Japan.
J Oral Pathol Med. 2001 Mar;30(3):141-7. doi: 10.1034/j.1600-0714.2001.300303.x.
Twenty-seven cases of primary extranodal oral B-cell lymphoma and 22 cases of primary maxillofacial nodal B-cell lymphoma were investigated for the presence of apoptotic cells and the expression of apoptosis-related gene products by terminal deoxynucleotidyl-mediated dUTP nick end labeling (TUNEL) and immunohistochemistry. The majority of extranodal oral diffuse large B-cell lymphomas (17/25, 68%) and maxillofacial nodal diffuse large B-cell lymphomas (14/16, 88%) contained no or less than 10% apoptotic cells. Whereas the majority of extranodal oral diffuse large B-cell lymphomas (18/25, 72%) and maxillofacial nodal diffuse large B-cell lymphomas (13/16, 81%) contained more than 10% of Ki-67-positive cells. Bcl-2-, Bax-, p53- and Ki-67-positive rates were higher in maxillofacial nodal diffuse large B-cell lymphomas than in extranodal oral diffuse large B-cell lymphomas, but only Bax (chi2 test, 0.01<P<0.025) and p53 (chi2 test, 0.005<P<0.01) had significant differences. Extranodal oral diffuse large B-cell lymphomas had a higher frequency of TUNEL expression than maxillofacial nodal diffuse large B-cell lymphomas. In maxillofacial nodal diffuse large B-cell lymphomas, stage III and stage IV tumors had a significantly higher frequency of Bcl-2 expression than stage I and stage II tumors (Fisher's exact test, P<0.01). These findings indicated that in the majority of both extranodal oral and maxillofacial nodal diffuse large B-cell lymphomas, apoptosis was inhibited - whereas proliferative activity was accelerated. Impairment of apoptosis and apoptotic related gene products may have a more important relation to maxillofacial nodal diffuse large B-cell lymphoma than extranodal oral diffuse large B-cell lymphoma.
对27例原发性结外口腔B细胞淋巴瘤和22例原发性颌面部淋巴结B细胞淋巴瘤进行研究，采用末端脱氧核苷酸转移酶介导的dUTP缺口末端标记法（TUNEL）和免疫组织化学方法检测凋亡细胞的存在及凋亡相关基因产物的表达。大多数结外口腔弥漫性大B细胞淋巴瘤（17/25，68%）和颌面部淋巴结弥漫性大B细胞淋巴瘤（14/16，88%）凋亡细胞数量为零或少于10%。而大多数结外口腔弥漫性大B细胞淋巴瘤（18/25，72%）和颌面部淋巴结弥漫性大B细胞淋巴瘤（13/16，81%）Ki-67阳性细胞超过10%。颌面部淋巴结弥漫性大B细胞淋巴瘤中Bcl-2、Bax、p53和Ki-67阳性率高于结外口腔弥漫性大B细胞淋巴瘤，但只有Bax（χ²检验，0.01<P<0.025）和p53（χ²检验，0.005<P<0.01）有显著差异。结外口腔弥漫性大B细胞淋巴瘤TUNEL表达频率高于颌面部淋巴结弥漫性大B细胞淋巴瘤。在颌面部淋巴结弥漫性大B细胞淋巴瘤中，Ⅲ期和Ⅳ期肿瘤Bcl-2表达频率显著高于Ⅰ期和Ⅱ期肿瘤（Fisher精确检验，P<0.01）。这些发现表明，在大多数结外口腔和颌面部淋巴结弥漫性大B细胞淋巴瘤中，凋亡受到抑制，而增殖活性加速。凋亡及凋亡相关基因产物的损害与颌面部淋巴结弥漫性大B细胞淋巴瘤的关系可能比结外口腔弥漫性大B细胞淋巴瘤更为重要。
